Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Bullboard Posts
Post by hanginthere99on Apr 23, 2015 10:17pm
164 Views
Post# 23659720

This stock is going nowhere.........Here are the facts!

This stock is going nowhere.........Here are the facts!Fact#1
Canadian government has provided $700,000 funding for pre-clinical studies and a Phase 1 clinical trial starting in 2016.

Fact#2
  iCO-008, which has been licensed out to Immune Pharmaceuticals, Inc. (IMNP). IMNP is running clinical trials for Inflammatory Bowel Disease, Severe Asthma & bullous pemphigoid and should have data in 2015 and 2016. ICO bears none of the costs of these studies but reaps the benefit of success.

Fact#3
the licensing agreement with IMNP which includes 654,486 shares, 123,649 warrants and $32 million in potential milestone payments. This page is the single most important one in understanding the motivation for ICO to be bought out.  Who would want to buy ICO?

Fact#4
IMNP itself makes a great candidate. ICO owns about 4% of IMNP which is valued at around $1.5 million USD (including the warrants) when IMNP is around $2. The working capital that's greater than the current stock price would also contribute to ICO's value. But the key to a buyout from IMNP's perspective would be in avoiding the $32 million in milestone payments and royalties on new sales.

Fact#5
When IMNP finalized this deal with ICO in June 2011, the stock price was around 10 times higher than it is today and market cap about 5 times higher. Now it just makes more sense to buy ICO out and not be subject to these payments.

Fact#6
$10 million would be a good starting point, putting the stock price at around 12 cents. A 20 cent buyout would cost $17 million, half of the milestone payments while also getting the working capital, IMNP shares and Amp B program as well.

Fact#7
IMNP has $7 million in cash for which it will use to develop iCO-008 and its other programs, so any buyout would likely come in the form of IMNP shares.

Fact#8
ICO is one to watch. Whether it's a buyout, as a bounce play or news from IMNP or the Amp B program, there are plenty of catalysts that will drive up the share price.
Read more at https://www.stockhouse.com/companies/bullboard/v.ico/ico-therapeutics-inc#IFJtBpEwsKM0kK5H.99

Fact#9
Allow all the skeptics, agnostics, atheist and doubters to be left behind!  All believers climb on board!  Two days ago we were just testing the rocket boosters, now it's time for the real launch!
The rocket has filled up with million of gallons of shares and is ready for take off!  Hang on, buckle up! we're going to the MOOOOOOOOOOOOOOOOOOOOOON!
Bullboard Posts